Digoxin Timelines: Unapproved Tablets Can Remain 30 Days, Elixirs Two Years
Executive Summary
Roxane Laboratories plans to submit an NDA for its digoxin elixir product in November, the company says
You may also be interested in...
FDA extends digoxin elixir NDA deadline
FDA extends deadline for companies to have an approved application for digoxin elixir from June 28 to Dec. 28. The extension was made because "it now appears that...there may not be any manufacturers prepared to market digoxin elixir under an approved application," a 1notice published in the June 29 Federal Register states. FDA set the original deadline in a final rule published June 28, 2002, which also required NDAs for digoxin tablets (2"The Pink Sheet" July 1, 2002, p. 12)...
FDA extends digoxin elixir NDA deadline
FDA extends deadline for companies to have an approved application for digoxin elixir from June 28 to Dec. 28. The extension was made because "it now appears that...there may not be any manufacturers prepared to market digoxin elixir under an approved application," a 1notice published in the June 29 Federal Register states. FDA set the original deadline in a final rule published June 28, 2002, which also required NDAs for digoxin tablets (2"The Pink Sheet" July 1, 2002, p. 12)...
FDA Seeks To Cut Abbott Synthroid Distribution To 60% By August 2002
An FDA guidance on levothyroxine products calls for Abbott to reduce Synthroid distribution to 60% of current levels by August 2002, about the time the company anticipates FDA approval for the drug.